Anti-TIGIT Antibody Binding CD155 Site for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer rely on immune checkpoint inhibitors, but there is a need for a novel antibody specifically targeting TIGIT, which has shown promise in inducing activation of immune cells to combat cancer, yet research on TIGIT-specific antibodies with high efficacy is insufficient.
Innovation Solution
Development of a novel anti-TIGIT antibody with high affinity for TIGIT overexpressed in cancer cells, specifically binding to the CD155 binding site to inhibit TIGIT/CD155 interaction, thereby activating immune cells and inhibiting tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1) are used for cancer treatment, then cancer therapy can be achieved, but there is insufficient efficacy and lack of novel therapeutic mechanisms
Solution Approach 1:
The invention segments the immune checkpoint inhibition approach by targeting a different receptor (TIGIT) compared to existing therapies (CTLA-4, PD-1, PD-L1). This segmentation into distinct therapeutic targets provides both proven efficacy through immune checkpoint inhibition and novel mechanism through TIGIT-specific blockade, resolving the contradiction between reliability and versatility
Solution Approach 2:
The anti-TIGIT antibody maintains the universal mechanism of immune checkpoint inhibition while adding versatility by targeting a different pathway. The antibody can function across multiple cancer types and can be combined with other immune checkpoint inhibitors, providing both reliable efficacy and adaptable therapeutic options
2Adaptability or versatility
If research focuses on developing TIGIT-specific antibodies, then novel therapeutic mechanisms can be achieved, but sufficient high-efficacy antibodies have not yet been developed
Solution Approach 1:
The invention applies parameter changes by optimizing the antibody's binding affinity to TIGIT and its ability to block the TIGIT-CD155 interaction. By adjusting these parameters during development and selection, the antibody achieves both novel mechanism through TIGIT targeting and high efficacy through optimized binding characteristics
3Force
If the antibody binds to TIGIT with high affinity, then immune cell activation can be enhanced, but specific binding to the CD155 site must be achieved to effectively inhibit TIGIT/CD155 interaction
Solution Approach 1:
The invention applies local quality by directing the antibody to bind specifically at the CD155 binding site on TIGIT rather than distributing binding across multiple sites. This localized binding at the critical interface maximizes the inhibition of TIGIT-CD155 interaction while maintaining high overall affinity, resolving the contradiction between binding strength and site-specific precision
Data Source
AI summary
Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition.The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.